PMID- 27524889
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160815
LR  - 20240325
IS  - 1177-889X (Print)
IS  - 1177-889X (Electronic)
IS  - 1177-889X (Linking)
VI  - 10
DP  - 2016
TI  - Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists 
      among injection-naive type 2 diabetes patients in Japan.
PG  - 1337-48
LID - 10.2147/PPA.S109289 [doi]
AB  - OBJECTIVE: The objective of this study was to use a discrete choice experiment 
      (DCE) to estimate patients' preferences for the treatment features, safety, and 
      efficacy of two specific glucagon-like peptide-1 receptor agonists, dulaglutide 
      and liraglutide, among patients with type 2 diabetes mellitus (T2DM) in Japan. 
      METHODS: In Japan, patients with self-reported T2DM and naive to treatment with 
      self-injectable medications were administered a DCE through an in-person 
      interview. The DCE examined the following six attributes of T2DM treatment, each 
      described by two levels: "dosing frequency", "hemoglobin A1c change", "weight 
      change", "type of delivery system", "frequency of nausea", and "frequency of 
      hypoglycemia". Part-worth utilities were estimated using logit models and were 
      used to calculate the relative importance (RI) of each attribute. A chi-square 
      test was used to determine the differences in preferences for the dulaglutide 
      versus liraglutide profiles. RESULTS: The final evaluable sample consisted of 182 
      participants (mean age: 58.9 [standard deviation =10.0] years; 64.3% male; mean 
      body mass index: 26.1 [standard deviation =5.0] kg/m(2)). The RI values for the 
      attributes in rank order were dosing frequency (44.1%), type of delivery system 
      (26.3%), frequency of nausea (15.1%), frequency of hypoglycemia (7.4%), weight 
      change (6.2%), and hemoglobin A1c change (1.0%). Significantly more participants 
      preferred the dulaglutide profile (94.5%) compared to the liraglutide profile 
      (5.5%; P<0.0001). CONCLUSION: This study elicited the preferences of Japanese 
      T2DM patients for attributes and levels representing the actual characteristics 
      of two existing glucagon-like peptide-1 receptor agonists. In this comparison, 
      dosing frequency and type of delivery system were the two most important 
      characteristics, accounting for >70% of the RI. These findings are similar to 
      those of a previous UK study, providing information about patients' preferences 
      that may be informative for patient-clinician treatment discussions.
FAU - Gelhorn, Heather L
AU  - Gelhorn HL
AD  - Outcomes Research, Evidera, Bethesda, MD.
FAU - Bacci, Elizabeth D
AU  - Bacci ED
AD  - Evidera, Seattle, WA.
FAU - Poon, Jiat Ling
AU  - Poon JL
AD  - Outcomes Research, Evidera, Bethesda, MD.
FAU - Boye, Kristina S
AU  - Boye KS
AD  - Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, 
      Indianapolis, IN, USA.
FAU - Suzuki, Shuichi
AU  - Suzuki S
AD  - Medicines Development Unit Japan, Eli Lilly Japan, Kobe, Japan.
FAU - Babineaux, Steven M
AU  - Babineaux SM
AD  - Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, 
      Indianapolis, IN, USA.
LA  - eng
PT  - Journal Article
DEP - 20160725
PL  - New Zealand
TA  - Patient Prefer Adherence
JT  - Patient preference and adherence
JID - 101475748
PMC - PMC4966566
OTO - NOTNLM
OT  - GLP-1 receptor agonists
OT  - discrete choice experiment
OT  - patient's preference
OT  - type 2 diabetes
OT  - willingness to inject
EDAT- 2016/08/16 06:00
MHDA- 2016/08/16 06:01
PMCR- 2016/07/25
CRDT- 2016/08/16 06:00
PHST- 2016/08/16 06:00 [entrez]
PHST- 2016/08/16 06:00 [pubmed]
PHST- 2016/08/16 06:01 [medline]
PHST- 2016/07/25 00:00 [pmc-release]
AID - ppa-10-1337 [pii]
AID - 10.2147/PPA.S109289 [doi]
PST - epublish
SO  - Patient Prefer Adherence. 2016 Jul 25;10:1337-48. doi: 10.2147/PPA.S109289. 
      eCollection 2016.